$MTNB News

Matinas BioPharma Hldgs Q1 EPS $(0.30) Up From $(0.33) YoY

Matinas BioPharma Hldgs Q4 EPS $(0.26) Up From $(1.68) YoY

Matinas BioPharma CFO Keith Kucinski Resigns; CEO Jerome Jabbour Appointed Interim CFO

Matinas Biopharma CFO Keith Kucinski To Resign Effective January 17, 2026

Matinas BioPharma Hldgs Q3 EPS $(0.40) Up From $(0.85) YoY

Matinas BioPharma Holdings, Inc. (MTNB) Restructures Amid Challenges, Focuses on Oral Antifungal MAT2203

Matinas BioPharma Doubles Authorized Common Shares To 500M Following Shareholder Approval

Matinas Biopharma Holdings shares are trading higher after the company announced it entered into a deal for the acquisition of certain preferred stock.

Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair

Matinas BioPharma Receives NYSE Noncompliance Notice

Matinas BioPharma downgraded to Neutral from Buy at Alliance Global Partners

Matinas BioPharma just downgraded at Alliance Global Partners, here's why

Matinas BioPharma plunges as deal for lead asset falls apart

Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction

Matinas BioPharma cut to Hold at Maxim on termination of MAT2203 talks

Matinas BioPharma downgraded to Hold from Buy at Maxim

Maxim gets more bearish on Matinas BioPharma, downgrades shares

Matinas BioPharma says MAT2203 partnership negotiations terminated

Matinas BioPharma Slashes Workforce Amid Financial Turmoil